First Experimental In Vivo Model of Enhanced Dengue Disease Severity through Maternally Acquired Heterotypic Dengue Antibodies

PLoS Pathogens

Volumn 10, Issue 4, 2014, Pages

  Ng, Jowin Kai Wei ^a   Zhang, Summer Lixin ^b   Tan, Hwee Cheng ^c   Yan, Benedict ^d   Maria Martinez Gomez, Julia ^a   Tan, Wei Yu ^a   Lam, Jian Hang ^a   Tan, Grace Kai Xin ^a   Ooi, Eng Eong ^c   Alonso, Sylvie ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Defence Science Organization National Laboratories   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VIRUS ANTIBODY;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DEATH; DENGUE; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOLOGY; HISTOLOGY; IN VIVO STUDY; LETHARGY; MALE; MOUSE; MUTANT; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; VASCULAR DISEASE; VASCULAR LEAKAGE; VIREMIA; VIRUS LOAD; ANIMAL; DISEASE MODEL; HAMSTER; IMMUNOLOGY; MUTANT MOUSE STRAIN; PASSIVE IMMUNIZATION; PATHOLOGY; PREGNANCY; SEVERITY OF ILLNESS INDEX;

ANIMALS; ANTIBODIES, VIRAL; CRICETINAE; CROSS REACTIONS; DENGUE; DISEASE MODELS, ANIMAL; FEMALE; IMMUNITY, MATERNALLY-ACQUIRED; MICE; MICE, MUTANT STRAINS; PREGNANCY; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901337156     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004031     Document Type: Article

References (64)

1. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, et al. (2010) Dengue: a continuing global threat. Nat Rev Microbiol 8: S7-16.
2. Halstead SB, (2007) Dengue. Lancet 370: 1644-1652.
3. Wright WF, Pritt BS, (2012) Update: The diagnosis and management of dengue virus infection in North America. Diagn Microbiol Infect Dis 73: 215-220.
4. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, et al. (2013) The global distribution and burden of dengue. Nature 496 (7446):: 504-7.
5. World Health Organization (2009). Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. WHO/HTM/NTD/DEN/2009.1.
6. Chambers TJ, Hahn CS, Galler R, Rice CM, (1990) Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 44: 649-688.
7. Simmons CP, Farrar JJ, Nguyen V, Wills B, (2012) Dengue. N Engl J Med 366: 1423-1432.
8. WHO (1997). Dengue hemorrhagic fever: diagnosis, treatment, prevention and control. 2nd edn. WHO, Geneva.
9. Edelman R, Hombach J, (2008) "Guidelines for the clinical evaluation of dengue vaccines in endemic areas": summary of a World Health Organization Technical Consultation. Vaccine 26: 4113-4119.
10. Halstead SB, (2012) Controversies in dengue pathogenesis. Paediatr Int Child Health 32 Suppl 1: 5-9.
11. Zompi S, Harris E, (2012) Animal models of dengue virus infection. Viruses 4: 62-82.
12. Guzman MG, Alvarez M, Halstead SB, (2013) Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol doi 10.1007s0070501316453/s00705-013-1645-3.
13. Halstead SB, (1970) Observations related to pathogenesis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med 42: 350-362.
14. Halstead SB, Simasthien P, (1970) Observations related to the pathogenesis of dengue hemorrhagic fever. II. Antigenic and biologic properties of dengue viruses and their association with disease response in the host. Yale J Biol Med 42: 276-292.
15. Halstead SB, (1990) Global epidemiology of dengue hemorrhagic fever. Southeast Asian J Trop Med Public Health 21: 636-641.
16. Rothman AL, (2011) Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 11: 532-543.
17. Boonnak K, Slike BM, Donofrio GC, Marovich MA, (2013) Human FcγRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection. J Immunol 190 (11):: 5659-5665.
18. Flipse J, Wilschut J, Smit JM, (2013) Molecular mechanisms involved in antibody-dependent enhancement of dengue virus infection in humans. Traffic 14 (1):: 25-35.
19. Chen RF, Yeh WT, Yang MY, Yang KD, (2001) A model of the real-time correlation of viral titers with immune reactions in antibody-dependent enhancement of dengue-2 infections. FEMS Immunol Med Microbiol 30: 1-7.
20. Littaua R, Kurane I, Ennis FA, (1990) Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol 144: 3183-3186.
21. Morens DM, Larsen LK, Halstead SB, (1987) Study of the distribution of antibody-dependent enhancement determinants on dengue 2 isolates using dengue 2-derived monoclonal antibodies. J Med Virol 22: 163-167.
22. Moi ML, Takasaki T, Saijo M, Kurane I, (2013) Dengue virus infection-enhancing activity of undiluted sera obtained from patients with secondary dengue virus infection. Trans R Soc Trop Med Hyg 107 (1):: 51-8.
23. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ, (2007) Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 104: 9422-9427.
24. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, et al. (2010) Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6: e1000790.
25. Zellweger RM, Prestwood TR, Shresta S, (2010) Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7: 128-139.
26. Kliks SC, Nimmanitya S, Nisalak A, Burke DS, (1988) Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38: 411-419.
27. Simmons CP, Chau TN, Thuy TT, Tuan NM, Hoang DM, et al. (2007) Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis 196 (3):: 416-24.
28. Chau TN, Hieu NT, Anders KL, Wolbers M, Lien le B, et al. (2009) Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. J Infect Dis 200 (12):: 1893-900.
29. Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, et al. (2010) Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci USA 107 (39):: 16922-7.
30. Chau TN, Quyen NT, Thuy TT, Tuan NM, Hoang DM, et al. (2008) Dengue in Vietnamese infants; results of infection-enhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J Infect Dis 198 (4):: 516-24.
31. Halstead SB, Lan NT, Myint TT, Shwe TN, Nisalak A, et al. (2002) Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg Infect Dis 8 (12):: 1474-9.
32. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, et al. (2009) A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med 6 (10):: e1000171.
33. Grant D, Tan GK, Qing M, Ng JK, Yip A, et al. (2011) A single amino acid in nonstructural protein NS4B confers virulence to dengue virus in AG129 mice through enhancement of viral RNA synthesis. J Virol 85: 7775-7787.
34. Schreiber MJ, Holmes EC, Ong SH, Soh HS, Liu W, et al. (2009) Genomic epidemiology of a dengue virus epidemic in urban Singapore. J Virol 83: 4163-4173.
35. Tan GK, Ng JK, Trasti SL, Schul W, Yip G, et al. (2010) A non mouse-adapted dengue virus strain as a new model of severe dengue infection in AG129 mice. PLoS Negl Trop Dis 4: e672.
36. Tan GK, Ng JK, Lim AH, Yeo KP, Angeli V, et al. (2011) Subcutaneous infection with non-mouse adapted Dengue virus D2Y98P strain induces systemic vascular leakage in AG129 mice. Ann Acad Med Singapore 40: 523-532.
37. Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E, (2006) Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol 80: 10208-10217.
38. Chan KR, Zhang SL, Tan HC, Chan YK, Chow A, et al. (2011) Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc Natl Acad Sci U S A 108: 12479-12484.
39. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, et al. (2000) Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 181: 2-9.
40. Libraty DH, Endy TP, Houng HS, Green S, Kalayanarooj S, et al. (2002) Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 185 (9):: 1213-21.
41. Basu A, Chaturvedi UC, (2008) Vascular endothelium: the battlefield of dengue viruses. FEMS Immunol Med Microbiol 53: 287-299.
42. Srikiatkhachorn A, (2009) Plasma leakage in dengue haemorrhagic fever. Thromb Haemost 102: 1042-1049.
43. Hober D, Poli L, Roblin B, Gestas P, Chungue E, et al. (1993) Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in dengue-infected patients. Am J Trop Med Hyg 48: 324-331.
44. Green S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Suntayakorn S, et al. (1999) Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis 179: 755-762.
45. Malavige GN, Huang LC, Salimi M, Gomes L, Jayaratne SD, et al. (2012) Cellular and cytokine correlates of severe dengue infection. PLOS one 7 (11):: e50387.
46. Atrasheuskaya A, Petzelbauer P, Fredeking TM, Ignatyev G, (2003) Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol Med Microbiol 35: 33-42.
47. Puerta-Guardo H, Sandino AR, González-Mariscal L, Rosales VH, Ayala-Dávila J, et al. (2013) The cytokine response of U937-derived macrophages infected through antibody-dependent enhancement of dengue virus disrupts cell apical-junction complexes and increases vascular permeability. J Virol 87 (13):: 7486-501.
48. Liu P, Woda M, Ennis FA, Libraty DH, (2009) Dengue virus infection differentially regulates endothelial barrier function over time through type I interferon effects. J Infect Dis 200 (2):: 191-201.
49. Hasselquist D, Nilsson JA, (2009) Maternal transfer of antibodies in vertebrates: trans-generational effects on offspring immunity. Philos Trans R Soc Lond B Biol Sci 364 (1513):: 51-60.
50. Jones M, Davidson A, Hibbert L, Gruenwald P, Schlaak J, et al. (2005) Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J Virol 79: 5414-5420.
51. Munoz-Jordan JL, Sanchez-Burgos GG, Laurent-Rolle M, Garcia-Sastre A, (2003) Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci U S A 100: 14333-14338.
52. Young DF, Chatziandreou N, He B, Goodbourn S, Lamb RA, et al. (2001) Single amino acid substitution in the V protein of simian virus 5 differentiates its ability to block interferon signaling in human and murine cells. J Virol 75: 3363-3370.
53. Johnson AJ, Roehrig JT, (1999) New mouse model for dengue virus vaccine testing. J Virol 73: 783-786.
54. Orozco S, Schmid MA, Parameswaran P, Lachica R, Henn MR, et al. (2012) Characterization of a model of lethal dengue virus 2 infection in C57BL/6 mice deficient in the alpha/beta interferon receptor. J Gen Virol 93 (Pt 10):: 2152-7.
55. van Panhuis WG, Luxemburger C, Pengsaa K, Limkittikul K, Sabchareon A, et al. (2011) Decay and persistence of maternal dengue antibodies among infants in Bangkok. Am J Trop Med Hyg 85: 355-362.
56. Fox A, Le NM, Simmons CP, Wolbers M, Wertheim HF, et al. (2011) Immunological and viral determinants of dengue severity in hospitalized adults in Ha Noi, Viet Nam. PLoS Negl Trop Dis 5 (3):: e967.
57. Pierson TC, Diamond MS, (2008) Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med 10: e12.
58. Whitehead SS, Blaney JE, Durbin AP, Murphy BR, (2007) Prospects for a dengue virus vaccine. Nat Rev Microbiol 5: 518-528.
59. Halstead SB, (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60: 421-467.
60. Morrison J, Aguirre S, Fernandez-Sesma A, (2012) Innate immunity evasion by Dengue virus. Viruses 4: 397-413.
61. Prestwood TR, Prigozhin DM, Sharar KL, Zellweger RM, Shresta S, (2008) A mouse-passaged dengue virus strain with reduced affinity for heparan sulfate causes severe disease in mice by establishing increased systemic viral loads. J Virol 82 (17):: 8411-21.
62. Lin CF, Wan SW, Cheng HJ, Lei HY, Lin YS, (2006) Autoimmune pathogenesis in dengue virus infection. Viral Immunol 19: 127-132.
63. Ventura AK, Ehrenkranz NJ, Rosenthal D, (1975) Placenta passage of antibodies to dengue virus in persons living in a region of hyperendemic dengue virus infection. J Infect Dis 131: S62-68.
64. Watanaveeradej V, Endy TP, Samakoses R, Kerdpanich A, Simasathien S, et al. (2003) Transplacentally transferred maternal-infant antibodies to dengue virus. Am J Trop Med Hyg 69: 123-128.